Sagimet Biosciences Inc. Comprehensive Income
Sagimet Biosciences Inc. (SGMT) reported Comprehensive Income of -$14.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$14.04M.
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$10.76M.
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$9.56M.
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$12.87M.
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$51.15M.
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$45.37M.
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$27.76M.
- Sagimet Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$30.58M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.04M 10-Q · filed 2026-08-11 | -$24.80M 10-Q · filed 2026-08-11 | -$34.37M derived: sum of 3 quarters · filed 2026-08-11 | -$47.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$10.76M 10-Q · filed 2026-05-12 | -$20.33M derived: sum of 2 quarters · filed 2026-05-12 | -$33.19M derived: sum of 3 quarters · filed 2026-05-12 | -$43.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$9.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$22.43M derived: sum of 2 quarters · filed 2026-03-11 | -$32.86M derived: sum of 3 quarters · filed 2026-08-11 | -$51.15M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$12.87M 10-Q · filed 2025-11-13 | -$23.30M derived: sum of 2 quarters · filed 2026-08-11 | -$41.58M 10-Q · filed 2025-11-13 | -$57.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$10.43M 10-Q · filed 2026-08-11 | -$28.72M 10-Q · filed 2026-08-11 | -$45.13M derived: sum of 3 quarters · filed 2026-08-11 | -$59.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$18.29M 10-Q · filed 2026-05-12 | -$34.70M derived: sum of 2 quarters · filed 2026-05-12 | -$48.85M derived: sum of 3 quarters · filed 2026-05-12 | -$57.00M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$16.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$30.57M derived: sum of 2 quarters · filed 2026-03-11 | -$38.72M derived: sum of 3 quarters · filed 2026-03-11 | -$45.37M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$14.15M 10-Q · filed 2025-11-13 | -$22.30M derived: sum of 2 quarters · filed 2025-11-13 | -$28.95M 10-Q · filed 2025-11-13 | -$37.08M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$8.15M 10-Q · filed 2025-08-13 | -$14.80M 10-Q · filed 2025-08-13 | -$22.92M derived: sum of 3 quarters · filed 2025-08-13 | -$29.27M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$6.65M 10-Q · filed 2025-05-08 | -$14.77M derived: sum of 2 quarters · filed 2025-05-08 | -$21.13M derived: sum of 3 quarters · filed 2025-05-08 | -$27.90M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$8.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$14.47M derived: sum of 2 quarters · filed 2025-03-12 | -$21.25M derived: sum of 3 quarters · filed 2025-03-12 | -$27.76M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$6.35M 10-Q · filed 2024-11-14 | -$13.13M derived: sum of 2 quarters · filed 2024-11-14 | -$19.64M 10-Q · filed 2024-11-14 | -$26.76M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$6.77M 10-Q · filed 2024-08-14 | -$13.29M 10-Q · filed 2024-08-14 | -$20.41M derived: sum of 3 quarters · filed 2024-08-14 | -$27.93M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$6.52M 10-Q · filed 2024-05-15 | -$13.63M derived: sum of 2 quarters · filed 2024-05-15 | -$21.16M derived: sum of 3 quarters · filed 2024-05-15 | -$28.36M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$14.64M derived: sum of 2 quarters · filed 2024-03-25 | -$21.85M derived: sum of 3 quarters · filed 2024-03-25 | -$30.58M 10-K · filed 2024-03-25 |
| 2022-09-30 | -$7.52M 10-Q · filed 2023-11-13 | -$14.73M derived: sum of 2 quarters · filed 2023-11-13 | -$23.47M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$7.21M 10-Q · filed 2023-08-21 | -$15.94M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |